Product Information
IBUPROFEN 100 MG/5 ML SUSP is a generic product labeled by Strides Pharma Inc., priced at $0.0246 per ML under NDC 64380099704. Its NADAC has been published 142 times since Jan 17, 2024.
FDA first approved this application on May 27, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
100 mg/5mL
Manufacturer
Strides Pharma Inc.NDC
64380099704
Classification
Generic
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
IBUPROFENApproval Type
Generic (ANDA)
FDA Application
ANDA215311FDA Approved
5/27/2022
TE Code
AB
On Market Since
9/19/2023
Pharmacological Classes
Price Statistics
The NADAC for IBUPROFEN 100 MG/5 ML SUSP has been published 142 times since Jan 17, 2024, and over the history we have for it it has risen 6.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0246 per ML |
|---|---|
| All-time high | $0.0278 (Sep 11, 2024) |
| All-time low | $0.0185 (Nov 20, 2024) |
| 52-week high | $0.0256 |
| 52-week low | $0.0236 |
| Median price | $0.0248 |
| Average price | $0.0243 |
| Largest weekly change | +29.7% (Aug 21, 2024) |
| Weeks tracked | 142 |
| Tracking since | Jan 17, 2024 |
Generic Alternatives
The matcher finds 10 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 4% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Strides Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ibuprofen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IBUPROFEN 100 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for IBUPROFEN 100 MG/5 ML SUSP, manufactured by Strides Pharma Inc., is $0.0246 per ML (NDC 64380099704), effective Sep 30, 2026.
How has the price of IBUPROFEN 100 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for IBUPROFEN 100 MG/5 ML SUSP has risen 6.2%. It has been tracked across 142 weekly CMS publications since Jan 17, 2024.
What are the highest and lowest recorded NADAC prices for IBUPROFEN 100 MG/5 ML SUSP?
Since Jan 17, 2024, the NADAC for IBUPROFEN 100 MG/5 ML SUSP has ranged from a low of $0.0185 (Nov 20, 2024) to a high of $0.0278 (Sep 11, 2024), with a median of $0.0248 per ML.
Are there cheaper alternatives to IBUPROFEN 100 MG/5 ML SUSP?
Yes. 10 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CHILDREN IBUPROFEN 100 MG/5 ML, is $0.0237 per ML — about 4% below IBUPROFEN 100 MG/5 ML SUSP.
Who manufactures IBUPROFEN 100 MG/5 ML SUSP?
IBUPROFEN 100 MG/5 ML SUSP (NDC 64380099704) is labeled by Strides Pharma Inc., and CMS classifies it as a generic product.